#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Pneumonia PIK3CA related overgrowth spectrum Metachromatic leukodystrophy Facioscapulohumeral muscular dystrophy Post transplant lymphoproliferative disorder Usher's syndrome Hereditary angioedema Microvillous inclusion disease Infertility male C3 glomerulopathy Acute myeloid leukaemia refractory Homocystinuria Conjunctivitis allergic Red blood cell abnormality Hodgkin's disease refractory More trials…

    Learn about Rare Diseases

    Primary hyperoxaluria – Diagnostics Anaplastic thyroid cancer – Diagnostics Nephrotic syndrome – Life with Disease Gaucher’s disease type I – Basic Information Wiskott-Aldrich syndrome – Life with Disease Rhabdoid tumour Krabbe’s disease – Life with Disease Hereditary angioedema with C1 esterase inhibitor deficiency Osteosarcoma – Treatment Chordoma – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    VRDN-003 Naloxone GSKVX000000040033 Saline GSKVX000000048111 Zinc Acetate Dihydrate Aflibercept Dog Epithelium Extract Lepidoglyphus Destructor Nortriptyline Lt3001 Zofenopril Calcium Crd-4730 SAROGLITAZAR HEMIMAGNESIUM Paroxetine Birtamimab ZIGAKIBART Spiramycin Pentixather 2-DEOXY-D-GLUCOSE More therapies…

    Learn about Your Condition

    Barrett's oesophagus Electronic cigarette user Eructation Infective uveitis Pancreatitis relapsing Insomnia Pneumonia bacterial Klinefelter's syndrome Endometrial cancer recurrent Arteriovenous malformation Head injury Ependymoma malignant Electrocorticogram Neuralgia Carpal tunnel syndrome More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Vaccine

  • Study of Pembrolizumab with Standard Chemoradiation for Patients with Advanced Anal Cancer

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Anal cancer
    Investigated Drugs:
    • Pembrolizumab
    Norway

  • Study of L19TNF (onfekafusp alfa) with temozolomide chemoradiotherapy for newly diagnosed glioblastoma patients

    Not yet recruiting

    1 1 1 1
    Investigated Diseases:
    • Glioma
    Investigated Drugs:
    • Onfekafusp Alfa
    • Temozolomide
    Germany Italy

  • Study on Preventing Acute Kidney Injury After Heart Surgery Using Empagliflozin in Patients Undergoing Elective Cardiac Surgery

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Cardiac function disturbance postoperative
    • Acute kidney injury
    Investigated Drugs:
    • Microcrystalline Cellulose
    • Empagliflozin
    Spain

  • A study evaluating a combination of glucagon and insulin lispro to improve insulin absorption in adults with Type 1 diabetes

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Type 1 diabetes mellitus
    Investigated Drugs:
    • Insulin Lispro
    • Glucagon
    Norway

  • Study on the Safety and Effects of Udonitrectag for Treating Diabetic Foot Ulcers in Patients

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Diabetic foot
    Investigated Drugs:
    • UDONITRECTAG
    Italy

  • Study on 68Ga-FAPI-46 PET Imaging for Patients with Gastrointestinal Cancers

    Not yet recruiting

    4 1 1
    Investigated Diseases:
    • Gastrointestinal cancer metastatic
    • Cholangiocarcinoma
    • Pancreatic carcinoma
    Investigated Drugs:
    • (S)-2,2′,2”-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
    Germany
Previous Page
1 … 824 825 826 827 828 … 1,674
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!